Evidence map›Paper›PMID 32036306›Full record

ReviewCurrent opinion in microbiology2020

Infection-based chemical screens uncover host-pathogen interactions.

Corrella S Detweiler

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Clofazimine Reduces the Survival ofACS infectious diseases · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Corrella S DetweilerDepartment of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80309, United States. Electronic address: detweile@colorado.edu.
University of Colorado Boulder · US

Funding

A Novel Screen for Antibacterials that Are Non-Toxic to MammalsR33AI121365 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S, WANG, XIANG · 2018 to 2020
$1.4M
Macrophages, Granulomas, and Bacterial PersistenceR21AI121474 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S, NAGY, TONI · 2016 to 2017
$423k
Chemical Probes for Bacteria-Macrophage InteractionsR21AI126453 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S · 2016 to 2017
$423k
A Novel Screen for Antibacterials that Are Non-Toxic to MammalsR21AI121365 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S, WANG, XIANG · 2016 to 2017
$412k
NIAID NIH HHS R21 AI121365NIAID NIH HHS R21 AI121474NIAID NIH HHS R21 AI126453NIAID NIH HHS R33 AI121365
6 · The paper itself

Abstract

Bacterial pathogens must resist host innate immunity to cause disease. While Gram-negative bacteria have a protective outer membrane, this membrane is subject to host-induced damage that makes these pathogens vulnerable. We developed a high content screening platform that identifies compounds that cause the killing of the bacterial pathogen Salmonella enterica in macrophages. This platform enables the rapid discovery of compounds that work in concert with the macrophage to prevent pathogen survival, as most hit compounds are not active in standard microbiological media and are not pro-drugs. We describe within the platform and the compounds it has found, and consider how they may help us discover new ways to fight infection.

Indexed as

Host-Pathogen InteractionsImmunity, InnateMicrobial Sensitivity TestsAnimalsAnti-Bacterial AgentsDrug DiscoveryMacrophagesMiceRAW 264.7 CellsSalmonella typhimuriumAnti-Bacterial Agents

Identifiers

PMID32036306
PMCPMC7247923
OpenAlexW3005418945

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.